Ibrexafungerp shows promise for women with recurrent vulvovaginal candidiasis in phase 3 clinical trial

Article

Scynexis released data from its pivotal Phase 3 CANDLE study of oral ibrexafungerp (BREXAFEMME) for the prevention of recurrent vulvovaginal candidiasis.

The antifungal ibrexafungerp is currently FDA-approved only for the treatment of vulvovaginal candidiasis (VVC), but data from Scynexis’ pivotal phase 3 trial also show encouraging results for the prevention of recurrent vulvovaginal candidiasis (RVVC), a condition for which there is currently no approved treatment.1

According to phase 3 results, ibrexafungerp successfully achieved significant superiority over placebo for the primary and secondary study endpoints. Scynexis will submit the data in a supplemental New Drug Application for ibrexafungerp oral tablets (BREXAFEMME®) to the FDA for approval as treatment for RVVC and anticipate a decision by the end of 2022.

The study comprised of 260 women who were experiencing RVVC, which is defined as 3 or more per year. All patients were given a 3-day regimen of open-label fluconazole and were then randomized to receive 300mg of ibrexafungerp 2 times daily for 1 day over a 6-month period, or a matching placebo 1 day per month over the same 6-month period.

Results showed 65.4% of patients receiving ibrexafungerp achieved clinical success by having no recurrence at all, either culture-proven, presumed or suspected, through week 24 compared to 53.1% of placebo-treated patients (p=0.02). The advantage of ibrexafungerp over placebo was sustained over the 3-month follow-up period and remained statistically significant (p=0.034).

Data were equally compelling for a subgroup of 24 patients that failed to respond to the initial 3-day regimen of fluconazole; for 71% of whom the 1-day treatment of ibrexafungerp substantially reduced or completely eliminated signs and symptoms.

The report indicated no serious drug-related adverse reactions and concluded ibrexafungerp to be generally safe and well-tolerated. Reported events included headaches and gastrointestinal events, which were mild and consistent with the existing drug label.

Reference

  1. SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022 :: SCYNEXIS, Inc. (SCYX). SCYNEXIS, Inc. Published February 10, 2022. Accessed February 10, 2022. https://ir.scynexis.com/press-releases/detail/273/scynexis-announces-positive-results-from-its-pivotal-phase

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Chemen M. Neal, MD, discusses weekly secnidazole for bacterial vaginosis treatment | Image Credit: medicine.iu.edu
Ryan Haumschild, PharmD
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
JoAnne Pinkerton, MD, FACOG, NCMP
Nannette Santoro, MD
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.